World's Best Scientists 2026 revealed!
Award Badge
Best Female Scientists
2025

D-Index & Metrics

Best Female Scientists

D-Index
132
Citations
81254
World Ranking
318
National Ranking
197

Medicine

D-Index
137
Citations
91090
World Ranking
1869
National Ranking
1062

Research.com Recognitions

  • 2025 - Research.com Best Female Scientists Award

Overview

Hope S. Rugo is affiliated with the University of California, San Francisco in the United States. Their research primarily focuses on medicine, with significant contributions to oncology and related fields such as pulmonary and respiratory medicine, cancer research, radiology, nuclear medicine, imaging, and genetics.

The scientist's work prominently covers topics including advanced breast cancer therapies, HER2/EGFR in cancer research, cancer treatment and pharmacology, breast cancer treatment studies, cancer immunotherapy and biomarkers, cancer genomics and diagnostics, and cancer-related molecular pathways.

Frequent publication venues for Hope S. Rugo include:

  • Journal of Clinical Oncology
  • Cancer Research
  • Annals of Oncology
  • Clinical Cancer Research
  • npj Breast Cancer

Notable recent papers authored or co-authored by Hope S. Rugo are:

  • Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer, 2022, New England Journal of Medicine
  • Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial, 2020, The Lancet
  • Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology, 2020, Journal of the National Comprehensive Cancer Network
  • Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer, 2021, New England Journal of Medicine
  • 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5), 2020, Annals of Oncology

Hope S. Rugo has collaborated extensively with several researchers, with frequent co-authors including:

  • Javier Cortés
  • Sara M. Tolaney
  • Aditya Bardia
  • Michelle Melisko
  • Sara A. Hurvitz

Best Publications

  • Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

    José Baselga;Mario Campone;Martine Piccart;Howard A. Burris

  • Palbociclib and Letrozole in Advanced Breast Cancer

    Richard S. Finn;Miguel Martin;Hope S. Rugo;Stephen Jones

  • Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

    Fabrice André;Eva Ciruelos;Gabor Rubovszky;Mario Campone

  • Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy

    David G. DeNardo;David G. DeNardo;Donal J. Brennan;Elton Rexhepaj;Brian Ruffell

  • 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

    F. Cardoso;A. Costa;E. Senkus;M. Aapro

  • Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.

    Jennifer K. Litton;Hope S. Rugo;Johannes Ettl;Sara A. Hurvitz

  • Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer

    Kathy D. Miller;Linnea I. Chap;Frankie A. Holmes;Melody A. Cobleigh

  • Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

    Paul M Ridker;Jean G MacFadyen;Tom Thuren;Brendan M Everett

  • Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

    Aditya Bardia;Sara A Hurvitz;Sara M Tolaney;Delphine Loirat

  • Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.

    Javier Cortes;David W Cescon;Hope S Rugo;Zbigniew Nowecki

  • Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

    William J. Gradishar;Benjamin O. Anderson;Jame Abraham;Rebecca Aft

  • Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer

    Kimberly L. Blackwell;Harold J. Burstein;Anna Maria Storniolo;Hope Rugo

  • Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

    Peter Schmid;Hope S Rugo;Sylvia Adams;Andreas Schneeweiss

  • Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

    Howard A. Burris;Hope S. Rugo;Svetislava J. Vukelja;Charles L. Vogel

  • Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells

    Brian Ruffell;Debbie Chang-Strachan;Vivien Chan;Alexander Rosenbusch;Alexander Rosenbusch

  • Breast Cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual

    Armando E. Giuliano;James L. Connolly;Stephen B. Edge;Elizabeth A. Mittendorf

  • T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

    Patrick A. Ott;Yung Jue Bang;Sarina A. Piha-Paul;Albiruni R. Abdul Razak

  • Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

    Sara M. Tolaney;William T. Barry;Chau T. Dang;Denise A. Yardley

  • Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

    Ayca Gucalp;Ayca Gucalp;Sara Tolaney;Steven J. Isakoff;James N. Ingle

  • Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

    José Baselga;Vladimir Semiglazov;Peter van Dam;Alexey Manikhas

Frequent Co-Authors

John W. Park
John W. Park University of California, San Francisco
Eric P. Winer
Eric P. Winer Yale University
Sara A. Hurvitz
Sara A. Hurvitz Fred Hutchinson Cancer Research Center
Laura J. Esserman
Laura J. Esserman University of California, San Francisco
Véronique Diéras
Véronique Diéras Institute Curie
Javier Cortes
Javier Cortes Vall d'Hebron Hospital Universitari
Joyce O'Shaughnessy
Joyce O'Shaughnessy Baylor University Medical Center
Mario Campone
Mario Campone Grenoble Alpes University
Christina Yau
Christina Yau University of California, San Francisco
Sara M. Tolaney
Sara M. Tolaney Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring careers in medicine doesn’t always require following a traditional path. For those interested in advanced nursing, the best dnp programs online offer doctoral-level education to become a nurse leader or advanced practice nurse while balancing other commitments.

Aspiring pharmacists can take advantage of 3-year online pharmd programs, making it possible to earn a Doctor of Pharmacy degree faster and with more flexibility than traditional offerings.

For those more interested in the administrative or tech side of healthcare, health information technology programs online are designed to prepare professionals for roles in managing electronic health records, compliance, and data security.

Finally, if you’re seeking a quick entry into the healthcare workforce, consider a medical coding certification online. This pathway provides the skills to handle billing and coding tasks—crucial for ensuring healthcare providers are reimbursed correctly.

Best Scientists Citing Hope S. Rugo

Trending Scientists